{
    "clinical_study": {
        "@rank": "156346", 
        "arm_group": [
            {
                "arm_group_label": "AZD1722", 
                "arm_group_type": "Active Comparator", 
                "description": "AZD1722 in 5, 15, 30, or 60 mg capsules.  Starting dose is 15 mg BID PO for 12 Weeks"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo capsule BID PO for 12 Weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if the study drug is safe, tolerable and active in\n      reducing albuminuria in patients with Chronic Kidney Disease with Type 2 Diabetes."
        }, 
        "brief_title": "A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Chronic Kidney Disease", 
            "Type 2 Diabetes Mellitus"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Albuminuria", 
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2", 
                "Kidney Diseases", 
                "Renal Insufficiency, Chronic", 
                "Kidney Failure, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males or females aged 18 to 80 years, inclusive.\n\n          -  Body mass index between 18 and 45 kg/m2, inclusive.\n\n          -  Type 2 diabetes mellitus and receiving \u22651 glucose lowering medication for at least 3\n             months prior to randomization\n\n          -  Stage 3 CKD\n\n          -  MSSBP \u2265130 mmHg\n\n          -  Urinary albumin: mean UACR \u2265 200 mg/g\n\n        Exclusion Criteria:\n\n          -  Urinary albumin: UACR > 3500 mg/g\n\n          -  History of a renal transplant\n\n          -  MSSBP >180 mmHg or a MSDBP of >120 mmHg on two occasions during screening or run-in\n             periods\n\n          -  History of inflammatory bowel disease or diarrhea predominant irritable bowel\n             syndrome"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "140", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01847092", 
            "org_study_id": "D5610C00001"
        }, 
        "intervention": [
            {
                "arm_group_label": "AZD1722", 
                "intervention_name": "AZD1722", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo for AZD1722", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "albuminuria", 
        "lastchanged_date": "January 24, 2014", 
        "location": {
            "contact": {
                "email": "jrecht47@comcast.net", 
                "last_name": "Judith Recht"
            }, 
            "facility": {
                "address": {
                    "city": "Denver", 
                    "country": "United States", 
                    "state": "Colorado", 
                    "zip": "80209"
                }, 
                "name": "Creekside Endocrine Associates PC"
            }, 
            "investigator": {
                "last_name": "Leonard Zemel, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Exploratory Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Design Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AZD1722 in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria", 
        "other_outcome": {
            "measure": "PD on u-Na excretion, mean weekly stool consistency and stool frequency", 
            "safety_issue": "No", 
            "time_frame": "Baseline to Week 12"
        }, 
        "overall_contact": {
            "email": "sedelstein@ardelyx.com", 
            "last_name": "Susan Edelstein, PhD"
        }, 
        "overall_contact_backup": {
            "email": "lmarshall@ardelyx.com", 
            "last_name": "Lori Marshall, MPH"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Changes in Urine Albumin to Creatinine Ratio   (UACR)", 
            "safety_issue": "No", 
            "time_frame": "Baseline to Week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01847092"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "PD effect on UACR, eGFR, blood pressure, p-NT-proBNP, s-cardiac troponin, u-aldosterone, p-renin activity, and bioimpedance", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline to Week 12"
        }, 
        "source": "Ardelyx", 
        "sponsors": {
            "collaborator": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Ardelyx", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}